ZVRA vs IQV vs CRL vs ICLR

For growth investors, Zevra Therapeutics, Inc.

(ZVRA) is the stronger pick with 350. 9% revenue growth year-over-year, versus -0. 9% for Charles River Laboratories International, Inc. (CRL). Zevra Therapeutics, Inc. (ZVRA) offers the better valuation at 8. 1x trailing P/E (22. 6x forward), making it the more compelling value choice. Analysts rate Zevra Therapeutics, Inc. (ZVRA) a "Buy" — based on 8 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

On trailing P/E, Zevra Therapeutics, Inc.

(ZVRA) is the cheapest at 8. 1x versus IQVIA Holdings Inc. at 22. 8x. On forward P/E, ICON Public Limited Company is actually cheaper at 10. 5x — notably different from the trailing picture, reflecting expected earnings growth. The PEG ratio (P/E divided by earnings growth rate) is the most growth-adjusted single valuation metric: IQVIA Holdings Inc. wins at 0. 35x versus ICON Public Limited Company's 1. 50x — a PEG below 1. 0 traditionally signals the market is underpricing earnings growth.

Over the past 5 years, Zevra Therapeutics, Inc.

(ZVRA) delivered a total return of +15. 8%, compared to -46. 9% for Charles River Laboratories International, Inc. (CRL). Over 10 years, the gap is even starker: IQV returned +166. 5% versus ZVRA's -90. 9%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), Zevra Therapeutics, Inc.

(ZVRA) is the lower-risk stock at 0. 63β versus ICON Public Limited Company's 1. 60β — meaning ICLR is approximately 153% more volatile than ZVRA relative to the S&P 500. On balance sheet safety, ICON Public Limited Company (ICLR) carries a lower debt/equity ratio of 38% versus 2% for IQVIA Holdings Inc. — giving it more financial flexibility in a downturn.

By revenue growth (latest reported year), Zevra Therapeutics, Inc.

(ZVRA) is pulling ahead at 350. 9% versus -0. 9% for Charles River Laboratories International, Inc. (CRL). On earnings-per-share growth, the picture is similar: Zevra Therapeutics, Inc. grew EPS 159. 2% year-over-year, compared to -1555. 0% for Charles River Laboratories International, Inc.. Over a 3-year CAGR, ZVRA leads at 118. 8% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

Zevra Therapeutics, Inc.

(ZVRA) is the more profitable company, earning 78. 2% net margin versus -3. 6% for Charles River Laboratories International, Inc. — meaning it keeps 78. 2% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: IQV leads at 14. 0% versus -4. 0% for ZVRA. At the gross margin level — before operating expenses — ZVRA leads at 84. 5%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

The PEG ratio (forward P/E divided by expected earnings growth rate) is the most precise measure of undervaluation relative to growth potential.

By this metric, IQVIA Holdings Inc. (IQV) is the more undervalued stock at a PEG of 0. 35x versus ICON Public Limited Company's 1. 50x. A PEG below 1. 0 is traditionally considered the threshold for growth-adjusted undervaluation. On forward earnings alone, ICON Public Limited Company (ICLR) trades at 10. 5x forward P/E versus 22. 6x for Zevra Therapeutics, Inc. — 12. 1x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for ZVRA: 120. 5% to $24. 25.

None of the stocks in this comparison currently pay a material dividend.

All are effectively zero-yield and should be held for capital appreciation rather than income.

For long-horizon retirement investors, Zevra Therapeutics, Inc.

(ZVRA) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0. 63)). ICON Public Limited Company (ICLR) carries a higher beta of 1. 60 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (ZVRA: -90. 9%, ICLR: +91. 0%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.

In terms of investment character: ZVRA is a small-cap high-growth stock; IQV is a mid-cap quality compounder stock; CRL is a small-cap quality compounder stock; ICLR is a small-cap deep-value stock. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.